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A B S T R A C T
In August 2018, Weiner and colleagues raised a red ﬂag concerning certain errors in the tables and ﬁgures of our article, “Amyloid pathology ﬁngerprint diﬀer-
entiates post-traumatic stress disorder and traumatic brain injury. NeuroImage Clinical 2018 Jun 5;19:716–726”. We have addressed this in detail in our published
“Corrigendum to ‘Amyloid pathology ﬁngerprint diﬀerentiates post-traumatic stress disorder and traumatic brain injury’ NeuroImage: Clinical. 19 (2018) 716–726”.
However, recently Prof. Weiner and colleagues have raised a new issue in indicating that they could not 'replicate our results, despite accurately emulating our
methods. We have prepared this letter in response to their recent letter.
Dear Dr. Dickerson
In August 2018, Weiner and colleagues raised a red ﬂag concerning
certain errors in the tables and ﬁgures of our article, “Amyloid pa-
thology ﬁngerprint diﬀerentiates post-traumatic stress disorder and
traumatic brain injury. NeuroImage Clinical 2018 Jun 5;19:716–726”
(Mohamed et al., 2018). We have addressed this in detail in our pub-
lished corrigendum (Mohamed et al., 2019), and have taken steps to
ensure that our data analysis pipeline is no longer vulnerable to clerical
errors. Happily, our main ﬁndings of distinct voxelwise patterns of re-
latively increased [18F]-AV45 SUVR in long-term PTSD and TBI survi-
vors have withstood re-analysis in our hands. Such focal group diﬀer-
ences of small eﬀect size are not at odds with the absent group
diﬀerences in Prof. Weiner's earlier analysis of the entire cerebral cortex
in these study groups (Weiner et al., 2017), as they would surely have
been diluted out in the large cortical volume of interest.
One of the major issues raised by Weiner et al. concerned our earlier
exclusion of non-Caucasian subjects and the lack of correction for age
and APOE4 status. We re-analyzed the data by adding 17 subjects ex-
cluded from our earlier analysis due to their ethnicity (results shown in
Fig. 1, below). The revised voxelwise ﬁndings closely matched Fig. 4 in
our original analysis (Mohamed et al., 2018), indicating that ethnicity is
not a major factor in our results. The extra 17 subjects distributed
among the existing groups as follows: n=0 (TBI), n= 2 (TBI_PTSD),
n=7 (PTSD), and n=8 (healthy controls).
In Fig. 1. We see higher relative [18F]-AV45 uptake in the supple-
mentary motor area, cerebellum, and precuneus of the TBI group, in the
white matter, the inferior parietal cortex, and the cingulate cortex of
the TBI_PTSD group, and in the temporal, occipital, and parietal lobes
of the PTSD group, all relative to the healthy control group. Further-
more, we ﬁnd substantially the same results upon inclusion of addi-
tional subjects of non-Caucasian ethnicity, and with the adjustment for
APOE4 status and age (Fig. 2, below), tested at the request of Prof.
Weiner.
Weiner et al. have gone to considerable trouble to emulate closely
our analysis methods using the same subject groups as in our publica-
tion, but have not replicated our voxelwise ﬁndings. We note two re-
maining issues that may account for Prof. Weiner's discrepant ﬁndings
with the same data:
1. Weiner et al. do not specify their method for image registration, i.e.,
FSL, ANTS, or SPM. Diﬀerent registration algorithms, software
versions, operating systems, and input arguments to the registration
commands might subtly alter parametric maps, resulting in false
positive or negative ﬁndings. As stated, we used FSL 5.0.9, which
gives in our hands diﬀerent results that its updated versions such as
5.0.10, 5.0.11, and 6.0.
2. Whereas we ﬁrst calculated SUVR maps in the native space, regis-
tered to the anatomic template, and then applied smoothing, Weiner
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et al. calculated their SUVR maps after registration and smoothing,
which likely results in diﬀerent biases due to resampling.
In general, if PET results are so very sensitive to minor methodo-
logical diﬀerences, one might suppose that the tracer and methods are
not completely ﬁt to detect reliably real group diﬀerences of small ef-
fect size. In this case, various re-analyses seemingly chatter around a
sensitivity limit established by the low speciﬁc binding of [18F]-AV45, a
ﬁrst-generation amyloid tracer. This issue is not without precedent in
PET imaging; consider the unreliable quantitation of [18F]-fallypride
Fig. 1. This ﬁgure shows the adjusted results of the original Fig. 4 of (Mohamed et al., 2018) after adding the 17 subjects who were excluded in our earlier analysis
because of their non-Caucasian ethnicity. The total number of subjects is then: n=21 (TBI), n= 31 (TBI_PTSD), n= 64 (PTSD), and n=65 (healthy controls).
Fig. 2. This ﬁgure shows the same contrasts in Fig. 4 from (Mohamed et al., 2018), but with the addition of 17 subjects who were excluded in our earlier analysis
because of their non-Caucasian ethnicity, and with results further adjusted for APOE4 status and age. The white matter ﬁnding in the TBI_PTSD group disappeared
after these adjustments. However, the ﬁndings of relatively higher [18F]-AV45 uptake in several cortical regions of the PTSD group, including the temporal, occipital,
and parietal cortex remained, as did the increased relative uptake in the supplementary motor area, cerebellum, and precuneus of the TBI group.
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binding to dopamine D2/3 receptors in the cerebral cortex, where the
BPND is only 0.5 (Smith et al., 2019). Returning to our topic of amyloid
imaging, ﬂorbetaben, ﬂorbetapir, and ﬂutemetamol all have similar
sensitivity and speciﬁcity for the diagnosis of Alzheimer's disease
(Morris et al., 2016), and might be similarly insensitive for detecting
the small group diﬀerences encountered in our analysis of TBI and
PTSD survivors. We can hope that improved amyloid tracers such as
ﬂuselenamyl, which has higher aﬃnity for amyloid and lower non-
speciﬁc binding in the white matter (Sundaram et al., 2016), should
help resolve this present issue. Furthermore, PET investigations of
amyloid in conditions other than Alzheimer's disease should also ac-
commodate the range of biophysical properties of diﬀerent kinds of
amyloid deposits (Shoghi-Jadid et al., 2005).
Indeed, the limits of sensitivity of present PET methods may be the
most important matter arising from this inquest, and one of general
interest to the readership of NeuroImage Clinical: if two similar and
valid approaches to data analysis give disparate results, then we must
be operating at the limit of the sensitivity of the methods. High sensi-
tivity is obtainable at the cost of false positive ﬁndings (Frackowiak
et al., 1996), but false negatives may arise from factors such as choice of
reference region, the precise extent of smoothing, or the ﬁltration of
individual parametric maps. We perceive a need for objective measures
of the sensitivity of a given method, perhaps obtainable through si-
mulations over a wide range of cluster and eﬀect sizes.
Respectfully,
Fatima A Nasrallah PhD. Queensland Brain Institute, The University
of Queensland, Brisbane, QLD 4072, Australia.
Paul Cumming PhD, Institute of Nuclear Medicine, Inselspital, Bern
University, Bern, Switzerland; School of Psychology and Counselling,
Queensland University of Technology, Queensland, Australia.
Abdalla Z Mohamed MSc, Queensland Brain Institute, The
University of Queensland, Brisbane, QLD 4072, Australia.
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